Drugs limiting excess mucus could save lives

November 26, 2012
Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions – excess mucus production. Now, researchers at Washington University School of Medicine in St. Louis have described the molecular pathway responsible for excess mucus in airway cells and have used that information to design a series of new drugs that inhibit that pathway. Specifically, Michael Holtzman, M.D., and his colleagues designed drugs (yellow) that bind with the MAPK13 enzyme (grey) to limit excess mucus production in airway cells. According to Holtzman, the drugs could help patients with life-threatening respiratory conditions including COPD and asthma. Credit: Michael J. Holtzman, M.D.

Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease (COPD) are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions – excess mucus production.

"There is good evidence that what kills people with severe or asthma is mucus obstructing the airway," says Michael J. Holtzman, MD, the Selma and Herman Seldin Professor of Medicine at Washington University School of Medicine in St. Louis. "It's a huge unmet medical problem and is only increasing in this country and throughout the world."

Now, Holtzman and his colleagues have described the molecular pathway responsible for excess mucus in and have used that information to design a series of that inhibit that pathway.

Their study appears online Nov. 26 in the .

Chronic respiratory disease, especially COPD, is the third leading cause of death in the United States and worldwide. Smoking and exposure to pollution are major causes of these diseases. Related conditions that affect the respiratory airways, like asthma and bronchitis, are also among the most common causes of human disease in adults and children. The morbidity and mortality from these conditions is closely linked to excess that blocks the airways and prevents normal breathing. However, there are no effective treatments to address the overproduction of airway mucus.

As part of the new research, the scientists discovered that a critical signaling molecule, CLCA1, has a special role in the mucus pathway. They showed that CLCA1 allows a protein known as IL-13 to turn on the major mucus gene in airway cells. The researchers also showed that CLCA1 needs help from an enzyme called MAPK13.

The video will load shortly
Respiratory conditions that restrict breathing such as asthma and chronic obstructive pulmonary disease are common killers worldwide. But no effective treatments exist to address the major cause of death in these conditions – excess mucus production. Now, researchers at Washington University School of Medicine in St. Louis have described the molecular pathway responsible for excess mucus in airway cells and have used that information to design a series of new drugs that inhibit that pathway. Credit: Washington University School of Medicine in St. Louis

Although there were no existing drugs that acted against MAPK13, Holtzman says there were several that inhibit a similar enzyme known as MAPK14, which differs slightly in structure.

"We could take advantage of the MAPK14 inhibitors that were already known," Holtzman says. "These drugs bind to a specific pocket in MAPK14 to block its activity. For MAPK13, that pocket itself has some obstructions making it more crowded and harder to access, so these older drugs can't fit into the pocket to block activity."

So Holtzman and his team built drugs with slimmer structures that could avoid the obstacles and better fit into the protein pocket of MAPK13.

"We sculpted the drugs so they're better able to bind in the MAPK13 pocket," Holtzman says. "And we showed that the new shape translates into more potent and effective blockade of MAPK13 activity. It's drug discovery that takes advantage of biology and chemistry, and it takes a very special team to do that."

Indeed, the results show that some of their newly designed MAPK13 inhibitors reduced mucus production in cultures of human airway cells by 100 fold.

Importantly, Holtzman says that this work had to be done in human cells because commonly used lab animals have different wiring for the mucus production circuit. For example, MAPK13 inhibitors were not effective in mice because other types of CLCA and MAPK proteins could continue to make excess mucus.

"We recognized that we had to work directly in human cells to figure out the control system," Holtzman says. "We then looked at lungs from patients with very severe COPD who were at the last resort of lung transplantation. In these diseased lungs, we found too much mucus, too much CLCA1 and over-activated MAPK13. What we observed in isolated translated to a devastating disease in real life."

Beyond COPD and asthma, Holtzman also sees a possible role for MAPK13 inhibitors in related conditions with excess mucus production, like cystic fibrosis and even the common cold.

"The big killer is COPD," Holtzman says. "But other extra-mucus conditions can also be life threatening. And we know from our studies that respiratory viral infections and allergies are potent activators of this same pathway for mucus production. Since the new inhibitors would be active in both the upper and lower airways, they could impact a wide set of respiratory illnesses."

Explore further: New airway stem cell found

More information: Alevy YG, Patel AC, Romero AG, Patel DA, Tucker J, Roswit WT, Miller CA, Heier RF, Byers DE, Brett TJ, Holtzman MJ. IL-13 induced airway mucus production is attenuated by MAPK13 inhibition. Journal of Clinical Investigation. Online Nov. 26, 2012.

Related Stories

New airway stem cell found

June 27, 2011
Researchers at UCLA have identified a new stem cell that participates in the repair of the large airways of the lungs, which play a vital role in protecting the body from infectious agents and toxins in the environment.

New proteins to clear the airways in cystic fibrosis and COPD

July 13, 2012
University of North Carolina scientists have uncovered a new strategy that may one day help people with cystic fibrosis and chronic obstructive pulmonary disorder better clear the thick and sticky mucus that clogs their lungs ...

Recommended for you

MRSA emerged years before methicillin was even discovered

July 19, 2017
Methicillin resistant Staphylococcus aureus (MRSA) emerged long before the introduction of the antibiotic methicillin into clinical practice, according to a study published in the open access journal Genome Biology. It was ...

New test distinguishes Zika from similar viral infections

July 18, 2017
A new test is the best-to-date in differentiating Zika virus infections from infections caused by similar viruses. The antibody-based assay, developed by researchers at UC Berkeley and Humabs BioMed, a private biotechnology ...

'Superbugs' study reveals complex picture of E. coli bloodstream infections

July 18, 2017
The first large-scale genetic study of Escherichia coli (E. coli) cultured from patients with bloodstream infections in England showed that drug resistant 'superbugs' are not always out-competing other strains. Research by ...

Ebola virus can persist in monkeys that survived disease, even after symptoms disappear

July 17, 2017
Ebola virus infection can be detected in rhesus monkeys that survive the disease and no longer show symptoms, according to research published by Army scientists in today's online edition of the journal Nature Microbiology. ...

Mountain gorillas have herpes virus similar to that found in humans

July 13, 2017
Scientists from the University of California, Davis, have detected a herpes virus in wild mountain gorillas that is very similar to the Epstein-Barr virus in humans, according to a study published today in the journal Scientific ...

Vaccines protect fetuses from Zika infection, mouse study shows

July 13, 2017
Zika virus causes a mild, flu-like illness in most people, but to pregnant women the dangers are potentially much worse. The virus can reduce fetal growth, cause microcephaly, an abnormally small head associated with brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.